breakthrough therapy drugs

President Donald Trump signed an executive order directing the FDA to expedite the review of psychedelics designated as breakthrough therapy drugs. The order aims to accelerate access to experimental treatments for severe mental illness and depression, particularly for veterans.

President Donald Trump signed an executive order directing the FDA to expedite reviews of psychedelics designated as breakthrough therapy drugs, aiming to accelerate access to treatments for severe mental illness and depression. The order emphasizes these therapies' potential to help veterans and patients in advanced clinical trials.